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Scan the quick response (QR) code to the left with your mobile device to watch this article's video abstract and others. Don't have a QR code reader? Get one by searching 'QR Scanner' in your mobile device's app store. C olorectal cancer (CRC) is the second leading cause of cancer-related deaths and the third most common diagnosed cancer in the United States. 1 The incidence and mortality rates of CRC have declined over the last 3 decades corresponding to multiple factors including increases in CRC screening rates. 2, 3 The US Preventive Services Task Force (USPSTF) recommends CRC screening between ages 50 and 75 in average-risk adults. 3 However, screening rates remain suboptimal, and it is estimated that further reductions in CRC incidence rates by 22% and mortality rates by 33% are possible if screening rates of 80% in the United States were achieved. 4 To capture the patients not up-to-date with CRC screening and to maintain high rates of CRC screening, organized population-based programs that include stool-based testing are needed. 5, 6 The USPSTF recommends the use of the fecal immunochemical test (FIT) as a stool-based test for CRC screening. 3 The Food and Drug Administration has cleared the use of many FITs in the United States for use in CRC screening programs and granted the tests a waived status under the Clinical Laboratory Improvement Amendments. 7 However, performance characteristics of many Food and Drug Administration-cleared FIT have not been evaluated in large average-risk populations and the quality of their development and interpretation have not been validated. FIT detects the globin moiety of human hemoglobin in the stool. 8 OC-Light FIT (Polymedco, Inc, Cortlandt Manor, New York) is a qualitative test analyzed by immunoassay methods and differs from quantitative FIT. 9 Qualitative FIT can be developed and interpreted at point-of-care, which raises concern for consistency in sample application and visual interpretation. The positivity threshold of qualitative FIT (cutoff concentration for a test to be positive) is set by the manufacturer and cannot be adjusted by the end user. In contrast, quantitative FIT, which is also Food and Drug Administration-cleared to provide only qualitative results, requires laboratory-based calibration using standard curves. The positivity cutoff can be adjusted, which allows the end user to adjust the sensitivity and specificity of the test. 10 The development and interpretation is automated after calibration and offers high throughput of specimens.
FIT sensitivity for CRC is estimated to be 75%, but has varied between 25% and 100% across different types of FIT tests, whereas the specificity has varied between 83% and 99%. 11 There are limited data on the real-life application of many qualitative FIT brands available in the United States or their positivity rates in average-risk population. Specific to OC-Light FIT, heterogeneity has been reported in the real-life application of the test, although USPSTF recommended the use of OC-Light FIT. The yield of colonoscopy for CRC using the OC-Light FIT has varied between 1.7% and 10.8%. [12] [13] [14] [15] [16] Therefore, the aim of the study was to evaluate the positive rate of the OC-Light FIT and the yield of colonoscopy after a positive result from a FIT in a diverse average-risk patient population in a safety-net system.
Methods

Study Design and Population
We conducted a retrospective cohort study of patients ages 50-75 in the San Francisco Health Network who received CRC screening by FIT between August 2010 and June 2015. The study cohort and setting have been previously described. 17 In short, San Francisco Health Network is an integrated health care safety-net system that delivers health services to uninsured, Medicaid, and other vulnerable residents of San Francisco. It is an integrated safety-net system comprised of 12 adult community health centers, a centralized laboratory, and a multispecialty medical center, the Zuckerberg San Francisco General Hospital and Trauma Center. 17 
Screening With Fecal Immunochemical Test
FIT testing with the OC-Light FIT tests started to be used in 2010 and were fully adopted across the system by 2012 as the primary form of CRC screening for average-risk individuals. The OC-Light test was provided to patients at a point-of-care visit and patients returned the completed test by mail to a central Zuckerberg San Francisco General Hospital and Trauma Center clinical laboratory, where it was processed. The OC-Light FIT is a lateral flow chromatographic immunoassay using immobilized antibodies specific to human hemoglobin, which provides qualitative results in the form of a visible reddish/pink line at a cutoff of 10 mg hemoglobin/g stool. 7 This cutoff is lower than that of the OC-Sensor FIT (Polymedco, Inc) (20 mg hemoglobin/g stool), which is the only other FIT in the United States recommended by the USPSTF. As a result, the OC-Light FIT is likely to have higher positive rate and sensitivity, and lower specificity compared with the OC-Sensor FIT.
Data Sources and Collection
San Francisco Health Network is supported by E-Clinical Works (eCW) as its primary outpatient electronic health record platform, which is linked to other data sources, such as the clinical laboratory and gastroenterology procedures. Demographic information, clinic details, and laboratory data of individuals with positive results from FIT were abstracted from patients' medical records. Receipt of colonoscopy was confirmed and findings were abstracted using the endoscopy software ProVation (ProVation Medical Inc, Minneapolis, MN). Pathology results were abstracted and reviewed using CoPathPlus platform (Cerner, Ontario, Canada).
Colonoscopy Data
Colonoscopy quality as measured by bowel preparation and cecal intubation rate was abstracted from procedure reports in ProVation. The quality of colonoscopy preparation was considered adequate if the endoscopist reported the preparation was adequate or at least fair and cecal intubation was achieved. 18 However, failure to reach the cecum in procedures with inadequate preparation were excluded from the calculation. 18 The adequacy of colonoscopy preparation rate was reported based on the first colonoscopy for patients with multiple colonoscopy reports following a positive FIT.
Pathologic Findings
Pathology reports were reviewed for the following findings: cancer, advanced adenoma, and advanced neoplasia. Advanced adenoma was defined as an adenoma that was 10 mm or more in diameter or any size with villous features or high-grade dysplasia. Advanced neoplasia was defined as cancer or advanced adenoma. Nonadvanced adenomas were not reported because clinically, they rarely if ever bleed. 19 Some patients had repeated colonoscopies for inadequate preparation or incomplete examination. Pathology findings were reported based on the most advanced lesion detected, which included subsequent colonoscopy if the initial colonoscopy was inadequate or incomplete.
Statistical Analysis
Patient demographic information was described as proportions, except age, which was described using medians and interquartile ranges. The FIT-positive rate was calculated as the number of positive results from FIT divided by the total number of FIT tests completed. The positive rate of FIT was further stratified into first round and subsequent rounds of testing. The primary outcome of the study was the yield or positive predictive value of colonoscopy for the detection of cancer and advanced adenomas after positive results from OC-Light FIT. Secondary endpoints included pathology findings by race and gender. Differences between groups of patients were assessed using chi-square and Student t test, as appropriate. The data were collected in Microsoft Excel then analyzed using STATA/IC version 14.2 (StataCorp LLC, College Station, TX). The study was approved by the institutional review board at University of California San Francisco (IRB 13-11900).
Results
Fecal Immunochemical Test Positivity Rate and Colonoscopy Completion
A total of 35,318 FIT tests were completed in 20,886 patients during the period of August 2010 to June 2015. The total number of patients with positive results from FIT was 2930 with an overall positive rate of 8.3%. The FIT-positive rate was higher in the first round compared with subsequent rounds (9.4% vs 7.4%; P < .01). Men had higher positive rate compared with women (10% vs 6.9%; P < .01). The rate of positive results from FIT was lowest among Asians (7.0%), followed by Hispanics (8.2%), then African Americans (11.7%) and nonHispanic whites (11.9%) (P < .01). FIT-positive rates stratified by gender and race are summarized in Table 1 .
Of patients with positive results from FIT, 1558 patients (53.2%) completed the follow-up colonoscopy procedure. Reasons for incomplete colonoscopy in this study population have been previously reported. 10 The median age of patients who had colonoscopy was 59.7. Among the patients completing the colonoscopy, 44.5% were Asian, 19.1% were non-Hispanic white, 16.2% were Hispanic, and 14.9% were African American (Table 1) . Patients who completed their colonoscopy had the following insurance coverage: Medicaid, 34.3%; Medicare, 33.6%; Healthy Worker, 22.2%; and Healthy San Francisco, 5.8%.
Yield of Colonoscopy Following Positive Results From Fecal Immunochemical Test
CRC was diagnosed in 3.0% of patients who underwent colonoscopy, advanced adenoma in 20.8%, and advanced neoplasia in 23.8% (Table 2 ). The yield of CRC in patients who had positive results from FIT during the first round of testing was 3.7%. During the subsequent rounds, the yield of CRC declined to 1.8% (3.7% vs 1.8%; P ¼ .02). Among the patients who completed their colonoscopy, the bowel preparation during the first colonoscopic examination was adequate in 91.5%. Overall, neoplasia was more frequent in men than women. Men were nominally more likely than women to be diagnosed with CRC following positive results from FIT, but this did not reach statistical significance (3.7% vs 2.4%; P ¼ .16). Similarly, men were more likely to have advanced adenoma (26.7% vs 15.5%; P < .01) and advanced neoplasia (30.4% vs 17.9%; P < .01) ( Table 3) .
Nominally, the rate of CRC was highest in Asians (3.8%), followed by non-Hispanic white (3.4%), Hispanic (2.0%), and African American patients (1.3%), although the absolute cases of CRC were small among African Americans (n ¼ 3) and Hispanics (n ¼ 5). Other pathologic findings were stratified by race and available in Supplementary Table 1 .
Discussion
This is the largest study of the OC-Light FIT evaluating its performance for CRC screening in a diverse average-risk safety net population. The results showed a positive rate of approximately 8% and a positive predictive value for CRC of 3%. These estimates vary by first round versus subsequent rounds of FIT testing. In this integrated safety-net system, OC-Light FIT effectively risks stratified patients for colonoscopy.
To our knowledge, our study is the largest to focus specifically on the OC-Light FIT; moreover, the population was diverse. Unlike most other screening programs, the OC-Light tests were developed and interpreted in a certified clinical laboratory. For these reasons, our results may be more reliable and reproducible than those reported from study settings or clinical practices where the tests were developed and interpreted in doctor's offices or noncertified laboratories. Before this study, the yield of colonoscopy for CRC ranged between 1.7% and 10.8%. Our study suggests that the yield of colonoscopy for CRC after a positive result from a FIT is 3.0%, which falls within the range reported in the literature (Supplementary Table 2) . [12] [13] [14] [15] [16] Given the size of our study, this is likely a valid estimate. As such, OC-Light FIT screening program can effectively allocate colonoscopy procedures by identifying 1 CRC case in 33 colonoscopy procedures instead of identifying 1 CRC case in 200 procedures.
OC-Light FIT has a 10 mg hemoglobin/g stool cutoff. Correspondingly, the FIT-positive rate in this study is higher than studies using other brands of FIT. Indeed, when the cutoff is less than 20 mg hemoglobin/g stool, the FIT-positive rate has ranged between 5.3% and 14.2%, whereas those that used a cutoff of 20-50 mg hemoglobin/ g stool, the range was between 1.4% and 7.5%. 12 Lower cutoff results in higher positive rates, which in turn results in lower positive predictive value for CRC. Given the 10 mg hemoglobin/g stool cutoff for OC-Light FIT, our results fall within the ranges reported in the literature. [12] [13] [14] [15] [16] It is notable that the positive rate of FIT and yield of CRC vary by gender and race. 2, 20 Gender has been strongly associated with differences in CRC incidence and mortality rates, where men have higher rates compared with women by 30% and 40%, respectively. 20, 21 Across race, our study showed that cancer detection rate was the highest among the Asian population, whereas their positive rate was the lowest. African Americans have historically had the highest CRC incidence and cancer-related mortality. 20 In our study, although we reported relatively higher FIT positive rates among African Americans, this did not result in downstream higher rates of CRC as reported in the literature. This limitation may be caused by differences in our sample size compared with population health studies. 20 The advanced neoplasia rate is fairly consistent across race, so the low CRC in African Americans may reflect the small sample size.
There are several limitations to this study. Because we sought to determine the real-life performance of OC-Light FIT, we were not able to calculate the sensitivity and specificity of the test as colonoscopy was not performed in all patients. Specifically, we did not have reliable long-term follow-up for each patient, which precluded our ability to examine whether negative results from FIT may have missed interval CRC. Moreover, the lack of follow-up colonoscopy for all individuals with positive FIT may have confounded the colonoscopy findings if differential follow-up occurs for those with and without colonic pathology. In particular, the colonic pathology may have been overestimated assuming that patients with CRC are more likely to complete their colonoscopy. However, given that FIT is used to screen average-risk asymptomatic individuals, most patients should be asymptomatic and therefore, differential follow-up should be limited. Any symptom would have prompted a direct referral for colonoscopy, which is readily accessible in this health system.
In conclusion, this study is a large real-life summary of the performance of OC-Light FIT in a diverse safetynet population. OC-Light seems to effectively identify high-risk individuals, resulting in high-yield colonoscopy procedures. It provides health systems with perspective on the colonoscopy demand and performance characteristics of OC-Light as a screening tool in diverse patient groups. 
